Applied Nutrition has reported a 43.9 per cent surge in profits to £41 million for the year to July 31, driven by surging demand from people taking weight-loss medications known as GLP-1s. The company said sales jumped 50.9 per cent as it launched a 'GLP1-Friendly Range' of products including protein shake sachets starting from £2, plus collagen and creatine supplements. The expansion comes as more than 6.3 per cent of British households now include at least one person using the medication, according to research by Worldpanel by Numerator.
Thomas Ryder, the company's founder and chief executive, said attitudes towards the drugs have shifted dramatically. He said: 'We were very hesitant to put 'GLP-1' anywhere near a product because it was quite secretive. It was quite taboo. People didn't openly talk about it. But then fast forward two years, and people are openly speaking about it.' He added: 'I wouldn't necessarily say they're proud of it, but they're very transparent with it, and you know some people are getting amazing results from it.' Ryder and colleagues tested the medication for several weeks earlier this year to understand what products users needed, finding that hydration and protein products helped users refuel when the medication made eating difficult.
The company has benefited from increased visibility through partnerships, including a collaboration with TV personality Coleen Rooney, who is an investor in the business. Ryder said the move helped widen appeal to female customers. The group also works with brands including Slush Puppie, Swizzels Love Hearts and Vimto. Ryder said young people continue to prioritise health by swapping 'night clubs for run clubs', even amid cost of living pressures.
However, the company faces headwinds. Applied Nutrition's London-listed shares fell 3 per cent as investors worried about margin pressure. Adam Vetesse, market analyst at investment platform Etoro, said higher whey protein costs and increased lower-margin US sales are expected to squeeze profitability next year, while heavy stock investment has hit cash conversion. The company acknowledged that whey protein prices had reached 'unprecedented levels' driven partly by GLP-1 demand, but Ryder said inflation was cooling and the firm hoped to pass costs to consumers next year.
Applied Nutrition is also expanding internationally, having paid £12 million to acquire US sports nutrition manufacturer Nutrablend Group, which includes a warehouse in Buffalo, New York and two brands, Basic and GR8 Lifestyle. Ryder said there is 'no sign of' weight-loss medication demand 'slowing down' and remains hopeful about sales prospects as the medication rolls out in pill form.
For savers and investors, the company's growth depends on managing whey protein cost inflation while maintaining margins as it scales its US operations.
